News on AD frontline:
Most recently, 1-21-2021, Stanford Medicine researchers published study in Nature. The study further proved the published results of Yale Medical 10-19-2017 and Temple Univ. Med School study on 1-31-2017, that deprivation of glucose is the cause of Alzheimer's disease. By research on myeloid cells in a dish and in living mice, they proved an inflammation mechanism. Even though the study did not dig deeper why glucose converting into glycogen, it explains our BrainGlucose role in saving mid-stage AD by pushing the equilibrium towards more glucose available for energy utilization after midnight, when more higher energy demanding and memory related REM dream cycles occur, which clearly prevents the classic symptoms of hallucinations, nightmares, and night sweats of nocturnal hypoglycemia in brain.
Company news: We are pleased to announce that ACL is granted new patents by USPTO and Canadian patent authority. They broaden our existing patent scope and place our AddMem device in a unique strategic position.
Currently, we own the following 4 patents:
U.S. PAT. NOs: 10,016,370; 10,953,025.
Canada PAT. N° 2.878.866
China PAT No. ZL201280041529.7
*****************************************************************************************
ACL is a company with patent granted technologies in brain science.
ACL is a licensed manufacturer by Pennsylvania State government for our medical food products.
After achieving miraculous therapy for early and mid stage Alzheimer’s patients by our flagship product BrainGlucose, Able Cerebral is migrating gradually to a pharmaceutical and medical device company in order to improve health in more areas:
1. Advancing our BrainGlucose to phase III clinical study so it can be available to more patients as a drug product.
2. Welcome Investments and Collaborations for continuing our efforts to develop AddMem, a non invasive medical device with game changing technologies for individualized memory recovery. It may benefit severe stage Alzheimer's, TBI (traumatic brain injury) and CTE (chronic traumatic encephalopathy).
3. These patented technologies is the basis of brain-machine interface. It can be the next AI (Artificial Intelligence) area to be explored based on our brain circuits theory--free energy, functional group interaction and memory protein stability equilibrium.
4. Expanding our technology and product line to appetite control / weight management (ChewFull), and digestive system strengthening (IBSshield).
Interested institutions for partnership and/or investment
Please contact:
Mr. Wayne Shentu
55 New Street, Ste. 14
Ephrata, PA 17522, U.S.
Tel: (717) 814-5752
communication@ablecerebral.com
In memory of Professor J. Howard Rytting, a diabetic and devoted his knowledge of thermodynamics to bio-pharmaceutical research
